This invention relates to compounds which are generally alpha-1B adrenergic receptor antagonists and which are represented by Formula (I): ##STR1## wherein R', R", R.sup.1, R.sup.2, m, n, and A are as defined in the specification, or acceptable prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

Esta invención se relaciona con los compuestos que son generalmente antagonistas adrenergic del receptor alfa-alpha-1B y que son representados por Formula (i): ## del ## STR1 en donde R ', R ", R.sup.1, R.sup.2, m, n, y A están según lo definido en la especificación, o prodrug, sal o solvate aceptable de eso. La invención más futura se relaciona con las composiciones farmacéuticas que contienen tales compuestos, los métodos para su uso como agentes terapéuticos, y los métodos de preparación de eso.

 
Web www.patentalert.com

< Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

< Substituted sulphonyl cyanamides, method for producing same and their use as medicament

> .beta.2-adrenergic receptor agonists

> Amorphous form of cell cycle inhibitor having improved solubility and bioavailability

~ 00070